Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism.
Nasdaq: AGIO
    
Publications
DateSourceTitle
03/09/17Keystone on Tumor MetabolismMetabolic collateral vulnerabilities of MTAP-deleted cancers as therapeutic opportunities
02/13/17Cancer Discovery AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
12/05/1658th ASH Annual MeetingDetermination of IDH1 Mutational Burden and Clearance via Next-Generation Sequencing in Patients With IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1
12/04/1658th ASH Annual MeetingEffects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase (PK) Deficiency: Data from the DRIVE PK Study
12/04/1658th ASH Annual MeetingCharacterization of metabolic response to AG-348, an allosteric activator of red cell pyruvate kinase, in healthy volunteers and pyruvate kinase deficiency patients
12/04/1658th ASH Annual MeetingIron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD)
12/04/1658th ASH Annual MeetingEnasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)
12/03/1658th ASH Annual MeetingSafety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of AG-519, an allosteric activator of pyruvate kinase-R in healthy subjects
12/03/1658th ASH Annual MeetingPopulation pharmacokinetics and pharmacodynamics of AG-519, a pyruvate kinase activator for the treatment of pyruvate kinase deficiency, in human healthy volunteers
11/18/162016 SNO Annual MeetingAG-120, a first-in-class mutant IDH1 inhibitor inpatients with recurrent or progressive IDH1mutant glioma: results from the phase 1 glioma expansion cohorts
11/10/162016 CTOS Annual MeetingA phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the chondrosarcoma dose escalation and expansion cohorts
10/11/16Cell ReportsDifferential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH
07/28/16Journal of Inherited Metabolic DiseaseA small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model
06/12/1621st EHA CongressPreclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator
06/11/1621st EHA CongressEffects of AG-348, a pyruvate kinase activator, on anemia and hemolysis in patients with pyruvate kinase deficiency: early data from the DRIVE-PK study
06/10/1621st EHA CongressThe pyruvate kinase activator AG-348 improves murine β-thalassemic anemia and corrects ineffective erythropoiesis
06/09/1621st EHA CongressA phase 1, single and multiple ascending dose study of safety, tolerability, pharmacokinetics and pharmacodynamics of AG-519, an allosteric activator of pyruvate kinase-R in healthy subjects
06/09/1621st EHA CongressAG-519 is a potent activator of mutant pyruvate kinase associated with hemolytic anemia
04/07/16Cell ReportsMTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
03/17/15Immunity JournalNetwork Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules that Regulate Macrophage Polarization
03/03/15PNAS JournalMutant IDH is sufficient to initiate enchondromatosis in mice
01/08/15Blood JournalIDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
12/12/14PLOS OneMesenchymal Phenotype Predisposes Lung Cancer Cells to Impaired Proliferation and Redox Stress in Response to Glutaminase Inhibition
07/02/14NatureMutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
03/25/14The Journal of Biological ChemistryBiochemical, Cellular and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1
04/02/13Science MagazineTargeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
04/01/13Science MagazineAn Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
09/02/12Chemistry & BiologySmall Molecule Activation of PKM2 in Cancer Cells Induces Serine Auxotrophy.
08/01/12Genes & DevelopmentD-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
07/17/12NatureIDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
03/22/12Science MagazineUnderstanding the Warburg effect: the metabolic requirements of cell proliferation.
03/20/12Cancer CellMetabolic reprogramming: a cancer hallmark even warburg did not anticipate.
02/15/12NatureTransformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
01/17/12The OncologistCancer-associated isocitrate dehydrogenase mutations.
12/20/11BiochemistryFull-length human glutaminase in complex with an allosteric inhibitor.
08/17/11NatureFunctional genomics reveal that the serine synthesis pathway is essential in breast cancer.
12/14/10Cancer CellLeukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation.
03/16/10Cancer CellThe Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting a-Ketoglutarate to 2-Hydroxyglutarate
02/15/10Journal of Experimental MedicineCancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
11/17/09NatureCancer-associated IDH1 mutations produce 2-hydroxyglutarate(2HG)